2- ((3- ((4- ((5- (2- ((3- fluorophenyl)amino)- 2- oxoethyl)- 1H- pyrazol- 3- yl)amino)quinazolin- 7- yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate

06/15/2007 - "The pharmacodynamic effects and efficacy of AZD1152 were determined in a panel of human tumor xenograft models. "
04/01/2013 - "In this Phase I trial, patients with advanced solid malignancies were treated with escalating doses of barasertib, administered as either a 48-h continuous infusion or as two 2-h infusions on consecutive days, both every 14 days of a 28-day cycle. "
10/01/2009 - "The aim of this study was to evaluate and to mechanistically explore scheduling effects of AZD1152 on tumor responses to IR, in three different settings: neoadjuvant (AZD1152 before IR), adjuvant (IR before AZD1152), or concomitant treatments (AZD1152 plus one single IR dose). "
04/25/2023 - "Our findings revealed that the treatment of AZD1152 exerted a non-specific anti-tumor effect. "
08/01/2018 - "AZD1152-HQPA (Barasertib) is a small selective inhibitor of AURKB activity and currently bears clinical assessment for several malignancies. "

10/01/2011 - "The safety, efficacy and pharmacokinetic (PK) profile of barasertib were investigated in Japanese patients with advanced acute myeloid leukemia. "
05/15/2009 - "AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo."
05/15/2009 - "In this study, we report the in vitro and in vivo activities of AZD1152, a compound that has selectivity for aurora B kinase, in acute myeloid leukemia (AML) cell lines, primary AML samples, and cord blood cells. "
07/01/2013 - "Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells."
04/01/2009 - "AZD1152 is a highly selective Aurora B kinase inhibitor currently undergoing Phase I and II clinical evaluation in patients with acute myelogenous leukemia and advanced solid malignancies. "

03/06/2023 - "Here, we tested the combination of TTFields with AZD1152, an Aurora B kinase inhibitor, in primary cultures of newly diagnosed (ndGBM) and recurrent glioblastoma (rGBM). "
03/06/2023 - "Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas."
10/01/2016 - "In this study, we analyzed the effects of selective Aurora B inhibition using AZD1152-HQPA/Barasertib (AZD1152) on HCT116 cells, U87-MG, corresponding isogenic p53-deficient cells and a primary glioblastoma cell line. "

02/22/2010 - "In addition, AZD1152 also inhibited pulmonary metastatic nodule formation in a metastatic breast cancer model. "
02/22/2010 - "AZD1152 administration efficiently suppressed the tumor growth in a breast cancer cell xenograft model. "
04/08/2015 - "with the highly selective kinase inhibitor barasertib, could be a candidate new treatment for breast cancer patients with acquired resistance to antiestrogens."
04/08/2015 - "The selective Aurora kinase B inhibitor barasertib was identified to preferentially inhibit growth of fulvestrant resistant T47D breast cancer cell lines. "
02/22/2010 - "It was shown that AZD1152 is an effective antineoplastic agent for breast cancer, and our results define a novel mechanism for posttranscriptional regulation of Aurora B after AZD1152 treatment and provide insight into dosing regimen design for this kinase inhibitor in metastatic breast cancer treatment."

02/01/2008 - "The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma."
02/22/2010 - "Preclinical antineoplastic activity of AZD1152 against acute myelogenous leukemia, multiple myeloma and colorectal cancer has been reported. "